Sera Prognostics (NASDAQ:SERA) CEO Zhenya Lindgardt Sells 7,022 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 7,022 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $2.00, for a total transaction of $14,044.00. Following the sale, the chief executive officer owned 837,848 shares in the company, valued at approximately $1,675,696. This trade represents a 0.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenya Lindgardt also recently made the following trade(s):

• On Tuesday, September 8th, Zhenya Lindgardt sold 20,139 shares of Sera Prognostics stock. The stock was sold at an average price of $2.00, for a total transaction of $40,278.00.

Sera Prognostics Price Performance

Shares of NASDAQ SERA opened at $2.03 on Friday. Sera Prognostics, Inc. has a 1 year low of $1.56 and a 1 year high of $3.95. The firm has a 50-day moving average of $2.05 and a 200 day moving average of $2.02. The stock has a market cap of $80.08 million, a P/E ratio of -3.03 and a beta of 0.98.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 47,475.72%.The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.07 million. Research analysts expect that Sera Prognostics, Inc. will post -0.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Weiss Ratings raised Sera Prognostics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Craig Hallum started coverage on shares of Sera Prognostics in a research note on Thursday, June 4th. They issued a “buy” rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sera Prognostics presently has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Institutional Investors Weigh In On Sera Prognostics

A number of large investors have recently added to or reduced their stakes in SERA. AWM Investment Company Inc. purchased a new stake in shares of Sera Prognostics in the 2nd quarter worth $377,000. Captrust Financial Advisors increased its stake in shares of Sera Prognostics by 20.0% in the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock worth $1,668,000 after purchasing an additional 100,366 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Sera Prognostics during the 1st quarter valued at $193,000. Jane Street Group LLC bought a new stake in shares of Sera Prognostics during the 4th quarter valued at $203,000. Finally, Vanguard Group Inc. lifted its stake in shares of Sera Prognostics by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock valued at $3,725,000 after buying an additional 54,008 shares in the last quarter. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.